Long-term follow-up of multiple sclerosis studies and outcomes from early treatment of clinically isolated syndrome in the BENEFIT 11 study
AbstractMultiple sclerosis (MS) is an autoimmune disease of the central nervous system (CNS) with a diverse disease course involving inflammation and degeneration of neurons and axons. Multiple sclerosis results from a complex interaction of genetic and environmental factors and clinically several disease subtypes with marked variation in symptoms can be discerned. Disease-modifying therapies (DMTs) impact disease activity and outcome. Long-term follow-up studies of DMTs in MS have generally shown that the short-term effects in clinical trials are maintained for up to 21 years, e.g. in the case of interferon beta-1b. Howev...
Source: Journal of Neurology - January 4, 2019 Category: Neurology Source Type: research
Cost-utility analysis of alemtuzumab in comparison with interferon beta, fingolimod, and natalizumab treatment for relapsing-remitting multiple sclerosis in Austria.
CONCLUSION: The analysis shows that alemtuzumab is a cost-saving alternative to treat RRMS in pretreated and therapy naïve patients. From the patient perspective alemtuzumab improves quality of life.
PMID: 30522373 [PubMed - as supplied by publisher] (Source: Journal of Medical Economics)
Source: Journal of Medical Economics - December 15, 2018 Category: Health Management Tags: J Med Econ Source Type: research
In silico analysis of different signal peptides to discover a panel of appropriate signal peptides for secretory production of Interferon-beta 1b in Escherichia coli.
The objective of this study was to identify a panel of signal peptides (among the 90 biologically active SPs) required for the secretory production of interferon-beta 1b (IFN-beta 1b) recombinant protein into the periplasmic space of E. coli host. In the initial step, after predicting the accurate locations of the cleavage sites of signal peptides and their discrimination scores using SignalP 4.1 server, 31 SPs were eliminated from further analysis because their discrimination scores were less than 0.5 or their cleavage sites were inappropriately located. Therefore, only 59 SPs could be theoretically applied to secrete IFN...
Source: Acta Biochim Pol - October 31, 2018 Category: Biochemistry Authors: Ghovvati S, Pezeshkian Z, Mirhoseini SZ Tags: Acta Biochim Pol Source Type: research
MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry
AbstractNeuroanatomical pattern classification using support vector machines (SVMs) has shown promising results in classifying Multiple Sclerosis (MS) patients based on individual structural magnetic resonance images (MRI). To determine whether pattern classification using SVMs facilitates predicting conversion to clinically definite multiple sclerosis (CDMS) from clinically isolated syndrome (CIS). We used baseline MRI data from 364 patients with CIS, randomised to interferon beta-1b or placebo. Non-linear SVMs and 10-fold cross-validation were applied to predict converters/non-converters (175/189) at two years follow-up ...
Source: Brain Imaging and Behavior - August 28, 2018 Category: Neurology Source Type: research
Sleep quality, daytime sleepiness, fatigue, and quality of life in patients with multiple sclerosis treated with interferon beta-1b: results from a prospective observational cohort study
Sleep disorders and fatigue are common in multiple sclerosis (MS). The underlying causes are not fully understood, and prospective studies are lacking. Therefore, we conducted a prospective, observational coho... (Source: BMC Neurology)
Source: BMC Neurology - August 24, 2018 Category: Neurology Authors: Sylvia Kotterba, Thomas Neusser, Christiane Norenberg, Patrick Bussfeld, Thomas Glaser, Martin D örner and Markus Schürks Tags: Research article Source Type: research
A Multiple Treatment Comparison of Eleven Disease-Modifying Drugs Used for Multiple Sclerosis.
Conclusions: Our results showed that alemtuzumab can be considered as more effective and less costly than the other treatment alternatives. There is a substantial potential cost saving if more patients start on the more effective and less costly treatment alternatives.
PMID: 29317954 [PubMed] (Source: Clin Med Res)
Source: Clin Med Res - January 12, 2018 Category: Research Authors: Hamidi V, Couto E, Ringerike T, Klemp M Tags: J Clin Med Res Source Type: research
Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing –remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study)
This study attempted evaluating the effects of fingolimod and interferon beta-1b (IFN β-1b) on CI progression, magnetic resonance imaging (MRI) and clinical outcomes in relapsing–remitting MS (RRMS) patients over 18 months. The GOLDEN study was a pilot study including RRMS patients with CI randomised (2:1) to fingolimod (0.5 mg daily)/IFN β-1b (250 µg every other day). CI was assessed via Rao’s Brief Repeatable Battery and Delis–Kaplan Executive Function System test. MRI parameters, Expanded Disability Status Scale scores and relapses wer e measured. Overall, 157 patients were randomised, of whom 30 discontinue...
Source: Journal of Neurology - October 23, 2017 Category: Neurology Source Type: research
Cost-Effectiveness Analysis of Alemtuzumab In Comparison With Natalizumab, Intramuscular Interferon Beta-1a, Subcutaneous Interferon Beta-1b, And Fingolimod for The Treatment of Relapsing-Remitting Multiple Sclerosis In Iran
In the era of representing new medicines for the treatment of Multiple sclerosis, a highly debilitating immune mediated disorder, evaluating the incremental cost-effectiveness of medicines are necessary for allocating health care resources in an efficient manner. Therefore, this study was aimed to to assess the cost-effectiveness of Alemtuzumab (ALM) in comparison with Natalizumab (NTZ), intramuscular interferon beta-1a (IM-IFN), subcutaneous interferon beta-1b (SC-IFN), and fingolimod (FNG) for the treatment of relapsing-remitting multiple sclerosis (RRMS) from Iranian healthcare perspective. (Source: Value in Health)
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: S Taheri, N Yousefi, MA Sahraian, G Mehralian Source Type: research
Cost-Effectiveness Analysis of Peginterferon Beta-1a Vs. First-Line Injectable Disease-Modifying Therapies For The Treatment of Relapsing-Remitting Multiple Sclerosis In Spain
This study assesses cost-effectiveness of subcutaneous (SC) peginterferon beta-1a 125 mcg SC every two weeks vs. other first-line injectable disease-modifying therapies (DMTs) such as glatiramer acetate 40mg SC daily, interferon beta-1a 30mcg intramuscular (IM) once a week, interferon beta-1a 44mcg SC three times a week, and interferon beta-1b 250mcg SC every other day, in the treatment of relapsing remitting multiple sclerosis (RRMS) from the payer perspective in Spain, over a 30-year time horizon (Source: Value in Health)
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: L Ruiz, H Toro-Diaz, C Cele, L Hernandez, A Harrington Source Type: research
Real World Characteristics and Perceived Efficacy of Peginterferon Beta-1A Compared with Other Platform Injectable Therapies Among MS Patients: Evidence in Five European Countries
Describe the demographic and disease characteristics of peginterferon beta-1a patients in a real world data set, and compare perceived effectiveness and quality of life of multiple sclerosis (MS) patients treated with peginterferon beta-1a versus other platform injectable therapies (IM interferon beta-1a, SC interferon beta-1a, interferon beta-1b, glatiramer acetate) in five European countries. (Source: Value in Health)
Source: Value in Health - October 1, 2017 Category: International Medicine & Public Health Authors: L Ruiz, J Zhou, C Wakeford, W Huang, Q Hou Source Type: research
Multiple Sclerosis and Subsequent Human Immunodeficiency Virus Infection: A Case with the Rare Comorbidity, Focus on Novel Treatment Issues and Review of the Literature
Conclusion: This fact, in combination with the unique pharmaceutical composition of the drug, which contains a component similar to a newly-approved agent for MS, dimethyl fumarate, prompted us to review the literature regarding this rare comorbidity and to suggest that the role of the antiretroviral therapy should be further explored in MS. (Source: In Vivo)
Source: In Vivo - September 7, 2017 Category: Research Authors: SKARLIS, C., GONTIKA, M., KATSAVOS, S., VELONAKIS, G., TOULAS, P., ANAGNOSTOULI, M. Tags: Clinical Studies Source Type: research
Aseptic steatonecrosis in a patient with multiple sclerosis with interferon-beta 1b treatment.
Authors: Ramos L, Busca C, Robles A
PMID: 28864085 [PubMed - as supplied by publisher] (Source: Medicina Clinica)
Source: Medicina Clinica - September 3, 2017 Category: General Medicine Tags: Med Clin (Barc) Source Type: research
MRI evidence of acute inflammation in leukocortical lesions of patients with early multiple sclerosis
Conclusions:
The presence of enhancing lesions affecting the cortex and adjacent white matter, although transient and not frequent, suggests that at least some cortical lesions are related to blood–brain barrier disruption. Our data support the concept that there may be an acute inflammatory phase in the development of leukocortical MS lesions.
Clinicaltrials.gov identifier:
NCT00176592. (Source: Neurology)
Source: Neurology - August 14, 2017 Category: Neurology Authors: Maranzano, J., Rudko, D. A., Nakamura, K., Cook, S., Cadavid, D., Wolansky, L., Arnold, D. L., Narayanan, S. Tags: MRI, Multiple sclerosis ARTICLE Source Type: research
Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
CONCLUSIONS: Very low-quality evidence suggests a small and uncertain benefit with early treatment compared with placebo in reducing disability-worsening and relapses. The advantage of early treatment compared with delayed on disability-worsening was heterogeneous depending on the actual drug used and based on very low-quality evidence. Low-quality evidence suggests that the chances of relapse are less with early treatment compared with delayed. Early treatment reduced the hazard of conversion to CDMS compared either with placebo, no treatment or delayed treatment, both in short- and long-term follow-up. Low-quality eviden...
Source: Cochrane Database of Systematic Reviews - April 25, 2017 Category: Journals (General) Authors: Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G Tags: Cochrane Database Syst Rev Source Type: research
Ocrelizumab (Ocrevus) for MS
Date: June 19, 2017
Issue #:
1523Summary:
The FDA has approved ocrelizumab (Ocrevus–
Genentech), a humanized anti-CD20 monoclonal
antibody, for treatment of adults with primary
progressive or relapsing multiple sclerosis (MS). It is the
first anti-CD20 monoclonal antibody to be approved for
treatment of MS and the first disease-modifying drug
to be approved in the US for primary progressive MS. (Source: The Medical Letter)
Source: The Medical Letter - April 19, 2017 Category: Drugs & Pharmacology Authors: admin Tags: Alemtuzumab Aubagio Avonex Betaseron Cladribine Copaxone daclizumab dimethyl fumarate Extavia Fingolimod Gilenya Glatiramer Glatopa Interferon beta IVIG Lemtrada Methotrexate mitoxantrone Multiple sclerosis Natalizuma Source Type: research
